MERCK KGAA

πŸ‡©πŸ‡ͺGermany
Ownership
Public
Established
1668-01-01
Employees
62.9K
Market Cap
$84.2B
Website
http://www.merckgroup.com/de

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

First Posted Date
2005-09-08
Last Posted Date
2014-06-25
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
1861
Registration Number
NCT00148798
Locations
πŸ‡¬πŸ‡§

Research Site, Wolverhampton, United Kingdom

Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)

First Posted Date
2005-07-29
Last Posted Date
2014-08-07
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
344
Registration Number
NCT00125034
Locations
πŸ‡ΊπŸ‡¦

Research Site, Vinnitsa, Ukraine

Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

Phase 1
Completed
Conditions
First Posted Date
2005-06-10
Last Posted Date
2014-02-19
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
26
Registration Number
NCT00113581
Locations
πŸ‡¬πŸ‡§

The Royal Marsden Hospital, London, United Kingdom

Β© Copyright 2024. All Rights Reserved by MedPath